fingolimod (Gilenya) vs ozanimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline

fingolimod (Gilenya)

Marketed by Novartis and partners

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT00289978 · Phase 3 · completed

This was a large randomized, triple-blind, placebo-controlled Phase 3 trial in 1,272 people with multiple sclerosis, using the annualized relapse rate as its primary measure. Both fingolimod doses roughly halved that rate against placebo: 0.16 relapses per year (95% CI 0.13 to 0.19) on 1.25 mg and 0.18 (95% CI 0.15 to 0.22) on 0.5 mg, against 0.40 (95% CI 0.34 to 0.47) on placebo. The registry posts these rates without a statistical test, but the intervals do not overlap, so the direction of the effect is not in doubt.

Next expected readout: January 2030 · NCT07220252 (registry estimate)

Reported efficacy

Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) (met)

Result source: NCT00289978

ozanimod · Zeposia

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple SclerosisSmall molecule (S1P1,5 modulator)
Partial signal

NCT01628393 · Phase 2/3 · completed

The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.

Next expected readout: August 2028 · NCT06529406 (registry estimate)

Reported efficacy

Adjusted Annualized Relapse Rate (ARR) at the End of Month 24: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose (met)

Result source: NCT02047734

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfingolimod (Gilenya)ozanimod
Annualised relapse rate0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
Free of 3-month confirmed disability progression (%)82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
—Trial running · NCT06408259
New or enlarging T2 lesions2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393

Annualised relapse rate

fingolimod (Gilenya)
0.2 vs 0.4−0.2 vs placebo0.5 mg · wk 104 · n 425NCT00289978
5 other results
  • 0.2 vs 0.4 0.5 mg · wk 104 · n 358 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 429 · Phase 3 · primary NCT00289978
  • 0.2 vs 0.4 1.25 mg · wk 104 · n 370 · Phase 3 · primary NCT00355134
  • 0.2 vs 0.4 0.5 mg · wk 234 · n 358 · Phase 3 · secondary NCT00355134
  • 0.2 vs 0.4 1.25 mg · wk 234 · n 370 · Phase 3 · secondary NCT00355134
ozanimod
0.2 vs 0.3vs Interferon Beta-1a1 mg · wk 96 · n 433NCT02047734
5 other results
  • 0.2 vs 0.3 1 mg · wk 52 · n 447 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.3 0.5 mg · wk 96 · n 439 · Phase 3 · primary NCT02047734
  • 0.2 vs 0.3 0.5 mg · wk 52 · n 451 · Phase 3 · primary NCT02294058
  • 0.2 vs 0.5 1 mg · wk 24 · n 83 · Phase 2/3 · secondary NCT01628393
  • 0.3 vs 0.5 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393

Free of 3-month confirmed disability progression (%)

fingolimod (Gilenya)
82.3% vs 75.9%+6.4 vs placebo0.5 mg · wk 104 · n 425NCT00289978
3 other results
  • 74.7% vs 71% 0.5 mg · wk 104 · n 358 · Phase 3 · secondary NCT00355134
  • 83.4% vs 75.9% 1.25 mg · wk 104 · n 429 · Phase 3 · secondary NCT00289978
  • 78.3% vs 71% 1.25 mg · wk 104 · n 370 · Phase 3 · secondary NCT00355134
ozanimod
—Trial running · NCT06408259

New or enlarging T2 lesions

fingolimod (Gilenya)
2.5 vs 9.8−7.3 vs placebo0.5 mg · wk 104 · n 370NCT00289978
1 other result
  • 2.5 vs 9.8 1.25 mg · wk 104 · n 337 · Phase 3 · secondary NCT00289978
ozanimod
0.8 vs 9−8.2 vs placebo1 mg · wk 24 · n 83NCT01628393
1 other result
  • 1.4 vs 9 0.5 mg · wk 24 · n 87 · Phase 2/3 · secondary NCT01628393
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fingolimod (Gilenya): 4 of 4 rows · ozanimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfingolimod (Gilenya)
Rows use multiple source trials
ozanimod
Rows use multiple source trials
Dropout rate
13.2%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
22.6%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
7.7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.4%1.25 mg
NCT00340834 · Phase 3 · monotherapy
13.2%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
22.6%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
9.1%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
13.8%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
43%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
15.7%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
31%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
18.2%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.5%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
8%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
7.5%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
14.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
12.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
5.2%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
9.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
15.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
6.8%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
24%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
32.2%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
2.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
19.1%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
21.7%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
—1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
1.2%1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
2.3%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
10.6%1 mg
NCT02047734 · Phase 3
15.6%0.5 mg
NCT02047734 · Phase 3
6.5%1 mg
NCT02294058 · Phase 3
5.8%0.5 mg
NCT02294058 · Phase 3
20.9%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
21%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
3.1%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
5.1%1.25 mg
NCT00289978 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
2.1%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
6.1%1.25 mg
NCT00340834 · Phase 3 · monotherapy
3.1%0.5 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3
—0.5 mg
NCT00662649 · Phase 3
5.1%1.25 mg
NCT00662649 · Phase 3 · monotherapy
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
0%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
2.3%0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—
NCT02232061 · Phase 4 · registry result, not featured evidence
15.2%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.7%
NCT01705236 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
4.5%FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
0.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
2%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
0.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
4.6%
NCT01623596 · Phase 4 · registry result, not featured evidence
9.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
4.8%
NCT01578330 · Phase 4 · registry result, not featured evidence
3%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
5.1%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
—0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
4.1%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
1.2%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.1%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
7.6%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
12.8%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
4.3%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
—1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
—1.0 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3%1 mg
NCT02047734 · Phase 3
2.9%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
1.6%0.5 mg
NCT02294058 · Phase 3
3%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
3.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
Serious AEs
10.1%0.5 mga
NCT00289978 · Phase 3 · monotherapy
show 44 more results
11.9%1.25 mg
NCT00289978 · Phase 3 · monotherapy
7%0.5 mg
NCT00340834 · Phase 3 · monotherapy
14.5%0.5 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00340834 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00340834 · Phase 3 · monotherapy
15.3%1.25 mg
NCT00340834 · Phase 3 · monotherapy
—1.25 mg
NCT00340834 · Phase 3 · monotherapy
—0.5 mg
NCT00662649 · Phase 3 · monotherapy
9.4%0.5 mg
NCT00662649 · Phase 3
7.1%0.5 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
10.7%1.25 mg
NCT00662649 · Phase 3
11.7%1.25 mg
NCT00662649 · Phase 3
—1.25 mg
NCT00662649 · Phase 3 · monotherapy
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
—0.5 mg
NCT04667949 · Phase 4 · registry result, not featured evidence
33.3%
NCT02232061 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
5.5%0.5 mg
NCT03257358 · Phase 4 · registry result, not featured evidence
12.6%
NCT01705236 · Phase 4 · registry result, not featured evidence
4.5%0.5 mg
NCT02373098 · Phase 4 · registry result, not featured evidence
—FTY720
NCT02373098 · Phase 4 · registry result, not featured evidence
2.3%
NCT01585298 · Phase 4 · registry result, not featured evidence
0%0.5 mg
NCT02720107 · Phase 4 · registry result, not featured evidence
5.5%Naive or de Novo Participants
NCT01498887 · Phase 4 · registry result, not featured evidence
2.7%Previously Treated With First-line
NCT01498887 · Phase 4 · registry result, not featured evidence
8.7%0.5 mg
NCT01333501 · Phase 4 · registry result, not featured evidence
6.7%
NCT01623596 · Phase 4 · registry result, not featured evidence
6.1%
NCT02048072 · Phase 4 · registry result, not featured evidence
9.5%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.9%0.5 mg
NCT01534182 · Phase 4 · registry result, not featured evidence
4%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
3.6%0.5 mg/day
NCT01216072 · Phase 4 · registry result, not featured evidence
12.6%0.5 mg/Day
NCT01201356 · Phase 3 · registry result, not featured evidence
7.4%0.5 mg
NCT01497262 · Phase 3 · registry result, not featured evidence
14.8%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
6.5%0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
14.3%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
8.8%1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
—1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
1.1%
NCT01199861 · Phase 3 · registry result, not featured evidence
17%0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
10.9%1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
7.3%1.0 mga
NCT01628393 · Phase 2/3
show 11 more results
—1 mg
NCT01628393 · Phase 2/3
0%1.0 mg
NCT01628393 · Phase 2/3
7.9%0.5 mg
NCT01628393 · Phase 2/3
—0.5 mg
NCT01628393 · Phase 2/3
3.4%0.5 mg
NCT01628393 · Phase 2/3
6.5%1 mg
NCT02047734 · Phase 3
7.1%0.5 mg
NCT02047734 · Phase 3
2.9%1 mg
NCT02294058 · Phase 3
3.5%0.5 mg
NCT02294058 · Phase 3
15.5%1.0 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
15.7%0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
0.5 mga
nasopharyngitis 27.1% (placebo 27.5%)
headache 25.2% (placebo 23%)
upper respiratory tract infection 17.2% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
show 34 more results
1.25 mg
headache 26.3% (placebo 23%)
nasopharyngitis 26.1% (placebo 27.5%)
upper respiratory tract infection 14.5% (placebo 17.2%)
NCT00289978 · Phase 3 · monotherapy
0.5 mg
headache 23.1%
nasopharyngitis 20.5%
fatigue 10.3%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 31%
headache 20.5%
lymphopenia 14.7%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
headache 22.9%
nasopharyngitis 22.1%
fatigue 14.3%
NCT00340834 · Phase 3 · monotherapy
1.25 mg
nasopharyngitis 31.3%
lymphopenia 21.4%
headache 17.1%
NCT00340834 · Phase 3 · monotherapy
0.5 mg
nasopharyngitis 25.4%
upper respiratory tract infection 17.5%
lymphopenia 15.7%
NCT00662649 · Phase 3
0.5 mg
nasopharyngitis 28.4%
headache 16.8%
upper respiratory tract infection 15.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 28.4%
lymphopenia 18%
upper respiratory tract infection 13.5%
NCT00662649 · Phase 3
1.25 mg
nasopharyngitis 26.9%
upper respiratory tract infection 15.9%
headache 12.4%
NCT00662649 · Phase 3
anxiety 16.7%
bursitis 16.7%
facet joint syndrome 16.7%
NCT02232061 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 8%
lymphopenia 5.5%
pain in extremity 5.5%
NCT03257358 · Phase 4 · registry result, not featured evidence
0.5 mg
fall 5.5%
urinary tract infection 3.2%
arthralgia 2.8%
NCT03257358 · Phase 4 · registry result, not featured evidence
nasopharyngitis 47.1%
multiple sclerosis relapse 24.1%
hypertension 13.8%
NCT01705236 · Phase 4 · registry result, not featured evidence
0.5 mg
influenza 3%
gamma-glutamyltransferase increased 1.5%
headache 1.5%
NCT02373098 · Phase 4 · registry result, not featured evidence
headache 4.5%
fatigue 3.2%
nasopharyngitis 2%
NCT01585298 · Phase 4 · registry result, not featured evidence
0.5 mg
blood immunoglobulin m decreased 0.8%
NCT02720107 · Phase 4 · registry result, not featured evidence
headache 8.5%
nasopharyngitis 8%
upper respiratory tract infection 7.5%
NCT01498887 · Phase 4 · registry result, not featured evidence
headache 11.6%
urinary tract infection 10.2%
upper respiratory tract infection 8.2%
NCT01498887 · Phase 4 · registry result, not featured evidence
0.5 mg
headache 10.6%
alanine aminotransferase increased 8.7%
depression 6.7%
NCT01333501 · Phase 4 · registry result, not featured evidence
fatigue 11.3%
nasopharyngitis 9.5%
headache 9.2%
NCT01623596 · Phase 4 · registry result, not featured evidence
exacerbation of migraines 3%
NCT02048072 · Phase 4 · registry result, not featured evidence
urinary infection 21.4%
upper respiratory infection 19%
lymphopenia 16.7%
NCT01578330 · Phase 4 · registry result, not featured evidence
0.5 mg
lymphopenia 11.7%
gamma-glutamyltransferase increased 5.7%
alanine aminotransferase increased 4.8%
NCT01534182 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 12.4%
fatigue 11.5%
upper respiratory tract infection 6.5%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/day
headache 9.8%
nausea 5.7%
fatigue 5.2%
NCT01216072 · Phase 4 · registry result, not featured evidence
0.5 mg/Day
nasopharyngitis 17.3%
headache 8.5%
upper respiratory tract infection 8.5%
NCT01201356 · Phase 3 · registry result, not featured evidence
0.5 mg
headache 13.6%
lymphopenia 10.5%
fatigue 6.2%
NCT01497262 · Phase 3 · registry result, not featured evidence
0.5 mg
upper respiratory tract infection 24.3% (placebo 24.2%)
nasopharyngitis 23.5% (placebo 23.9%)
headache 23.2% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16% (placebo 23.9%)
upper respiratory tract infection 12.3% (placebo 24.2%)
headache 9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
upper respiratory tract infection 24.9% (placebo 24.2%)
nasopharyngitis 23.8% (placebo 23.9%)
headache 21.9% (placebo 21.4%)
NCT00355134 · Phase 3 · registry result, not featured evidence
1.25 mg
nasopharyngitis 16.2% (placebo 23.9%)
upper respiratory tract infection 15.9% (placebo 24.2%)
sinusitis 10.1% (placebo 12.7%)
NCT00355134 · Phase 3 · registry result, not featured evidence
headache 18.9% (placebo 9.3%)
nasopharyngitis 15.8% (placebo 18.6%)
upper respiratory tract infection 11.6% (placebo 14%)
NCT01199861 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 61.7%
headache 17%
liver function test abnormal 12.8%
NCT00670449 · Phase 2 · registry result, not featured evidence
1.25 mg
nasopharyngitis 60.9%
liver function test abnormal 17.4%
lymphopenia 17.4%
NCT00670449 · Phase 2 · registry result, not featured evidence
1.0 mga
nasopharyngitis 13.8% (placebo 13.6%)
alanine aminotransferase increased 9.8% (placebo 0%)
upper respiratory tract infection 8.9% (placebo 3.4%)
NCT01628393 · Phase 2/3
show 9 more results
1.0 mg
gamma-glutamyltransferase increased 6% (placebo 0%)
nasopharyngitis 6% (placebo 13.6%)
alanine aminotransferase increased 4.8% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
upper respiratory tract infection 15.9% (placebo 3.4%)
nasopharyngitis 13.5% (placebo 13.6%)
gamma-glutamyltransferase increased 8.7% (placebo 0%)
NCT01628393 · Phase 2/3
0.5 mg
nasopharyngitis 12.6% (placebo 13.6%)
urinary tract infection 6.9% (placebo 2.3%)
back pain 5.7% (placebo 10.2%)
NCT01628393 · Phase 2/3
1 mg
nasopharyngitis 15.7%
headache 10.1%
upper respiratory tract infection 7.8%
NCT02047734 · Phase 3
0.5 mg
nasopharyngitis 13.4%
headache 12.5%
upper respiratory tract infection 8.2%
NCT02047734 · Phase 3
1 mg
headache 7.6%
nasopharyngitis 6.7%
upper respiratory tract infection 4%
NCT02294058 · Phase 3
0.5 mg
nasopharyngitis 9.7%
upper respiratory tract infection 6.8%
headache 6%
NCT02294058 · Phase 3
1.0 mg
nasopharyngitis 20.9% (placebo 13.5%)
headache 17% (placebo 5.4%)
covid-19 16.1% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 21% (placebo 13.5%)
headache 16.9% (placebo 5.4%)
covid-19 15.5% (placebo 21.6%)
NCT02576717 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fingolimod (Gilenya)

EDSS 3mo Disability Progression-free 82.3% (n=425) vs 75.9% (n=418) placebo @ 104wk0.5 mg
responder rate · % of participants
NCT00289978 · Phase 3 · monotherapy
show 3 more results
74.7% (n=358) vs 71% (n=355) placebo @ 104wk0.5 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
83.4% (n=429) vs 75.9% (n=418) placebo @ 104wk1.25 mg
NCT00289978 · Phase 3 · monotherapy
78.3% (n=370) vs 71% (n=355) placebo @ 104wk1.25 mg
NCT00355134 · Phase 3 · registry result, not featured evidence
Annualized Relapse 0.161 per year @ 52wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 17 more results
0.182 per year @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.11 per year @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.539 per year @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.227 per year @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.166 per year @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.191 per year @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.164 per year @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.203 per year @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.156 per year @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.116 per year @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
NA per year @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.404 per year @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.284 per year @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.223 per year @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.058 per year @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
0.075 per year @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
New T2 Lesion 1.6 T2 lesions @ 52wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 7 more results
0.87 T2 lesions @ 104wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.04 T2 lesions @ 156wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
0.59 T2 lesions @ 208wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
1.6 T2 lesions @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.08 T2 lesions @ 104wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
1.4 T2 lesions @ 156wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
0.97 T2 lesions @ 208wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
EDSS 3mo Disability Progression-free 94.1% (n=429) @ 52wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 1 more result
93.3% (n=420) @ 52wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Annualized Relapse 0.166 per year @ 234wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
show 1 more result
0.192 per year @ 234wk1.25 mg
Month 0 to end of study, n=420, 429, 431
NCT00340834 · Phase 3 · monotherapy
New T2 Lesion 0.86 T2 lesions @ 234wk0.5 mg
event count · T2 lesions
Extension (open-label)
No placebo or comparator arm
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
show 1 more result
1.75 T2 lesions @ 234wk1.25 mg
Last MRI scan to end of study, n=275, 309, 290
NCT00340834 · Phase 3 · monotherapy
EDSS 6mo Disability Progression Free 71.28% (n=429) @ 13wk0.5 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00340834 · Phase 3 · monotherapy
show 3 more results
79.76% (n=429) @ 26wk0.5 mg
NCT00340834 · Phase 3 · monotherapy
67.01% (n=420) @ 13wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
79.54% (n=420) @ 26wk1.25 mg
NCT00340834 · Phase 3 · monotherapy
Relapse Rate Annualized 0.185 per year @ 260wk0.5 mg
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 9 more results
0.111 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.292 per year @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.095 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.13 per year @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.064 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.301 per year @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.074 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.164 per year @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
Relapse-free 59.29% (n=425) @ 260wk0.5 mg
absolute value · percentage points
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 1 more result
59.85% (n=429) @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
no New or Enlarged T2 Lesion 50.3% (n=163) @ 104wk0.5 mg
absolute value · percentage points
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 23 more results
23.2% (n=69) @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.3% (n=163) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
55.1% (n=69) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
69.4% (n=57) @ 13wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
86% (n=57) @ 26wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.6% (n=57) @ 39wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
93.2% (n=57) @ 52wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
88.4% (n=57) @ 78wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
94.9% (n=57) @ 104wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92% (n=57) @ 156wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=57) @ 208wk0.5 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
53.2% (n=126) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
18.5% (n=65) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
57.1% (n=126) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
52.3% (n=65) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
60% (n=54) @ 13wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
91.5% (n=54) @ 26wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 39wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
95.2% (n=54) @ 52wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90% (n=54) @ 78wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
92.3% (n=54) @ 104wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
90.5% (n=54) @ 156wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
100% (n=54) @ 208wk1.25 mg
NCT00670449 · Phase 2 · registry result, not featured evidence
Brain Volume -0.983% (n=330) @ 104wk0.5 mg
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 9 more results
-1.419% (n=154) @ 104wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-0.78% (n=330) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-0.903% (n=154) @ 208wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-1.674% (n=299) @ 260wk0.5 mg
NCT00662649 · Phase 3 · monotherapy
-1.011% (n=287) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.511% (n=145) @ 104wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-0.871% (n=287) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.103% (n=145) @ 208wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
-1.639% (n=250) @ 260wk1.25 mg
NCT00662649 · Phase 3 · monotherapy
Relapse 0.85 per year0.5 mg
ratio to baseline · per year
Extension (open-label)
No placebo or comparator arm
NCT00662649 · Phase 3 · monotherapy
show 3 more results
0.446 per year0.5 mg
NCT00662649 · Phase 3 · monotherapy
1.164 per year1.25 mg
NCT00662649 · Phase 3 · monotherapy
0.547 per year1.25 mg
NCT00662649 · Phase 3 · monotherapy

+ 142 further endpoints in the CSV export.

ozanimod

Gadolinium Enhancing Lesion 1.5 vs 11.1 placebo lesions @ 24wk1 mg
event count · lesions
NCT01628393 · Phase 2/3
show 7 more results
0.2 vs 3.2 placebo lesions @ 24wk1 mg
NCT01628393 · Phase 2/3
0.176 vs 0.373 Interferon Beta-1a lesions @ 96wk1 mg
NCT02047734 · Phase 3
0.16 vs 0.433 Interferon Beta-1a lesions @ 52wk1 mg
NCT02294058 · Phase 3
1.9 vs 11.1 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.4 vs 3.2 placebo lesions @ 24wk0.5 mg
NCT01628393 · Phase 2/3
0.197 vs 0.373 Interferon Beta-1a lesions @ 96wk0.5 mg
NCT02047734 · Phase 3
0.287 vs 0.433 Interferon Beta-1a lesions @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 1.835 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk1 mg
event count · lesions/scan
NCT02047734 · Phase 3
show 1 more result
2.092 vs 3.183 Interferon Beta-1a lesions/scan @ 96wk0.5 mg
NCT02047734 · Phase 3
Time to 3m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
Time to 6m Confirmed Disability Worsening NA vs NA Interferon Beta-1a months1 mg
time to event · months
NCT02047734 · Phase 3
show 3 more results
NA vs NA Interferon Beta-1a months1 mg
NCT02294058 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02047734 · Phase 3
NA vs NA Interferon Beta-1a months0.5 mg
NCT02294058 · Phase 3
MRI Gadolinium Lesion-Free 65.6% (n=433) vs 56.2% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 3 more results
74.05% (n=447) vs 63.17% (n=448) Interferon Beta-1a @ 52wk1 mg
NCT02294058 · Phase 3
63.3% (n=439) vs 56.2% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
68.29% (n=451) vs 63.17% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
no New or Enlarged T2 Lesion 23.8% (n=433) vs 18.4% (n=441) Interferon Beta-1a @ 96wk1 mg
responder rate · % of participants
NCT02047734 · Phase 3
show 1 more result
23.5% (n=439) vs 18.4% (n=441) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
Whole Brain Volume -0.707% (n=390) vs -0.937% (n=397) Interferon Beta-1a @ 96wk1 mg
percent change · % of baseline
NCT02047734 · Phase 3
show 3 more results
-0.69% (n=271) vs -0.94% (n=279) Interferon Beta-1a @ 96wk1 mg
NCT02047734 · Phase 3
-0.707% (n=398) vs -0.937% (n=397) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.71% (n=274) vs -0.94% (n=279) Interferon Beta-1a @ 96wk0.5 mg
NCT02047734 · Phase 3
MSFC -0.01 vs -0.052 Interferon Beta-1a Z-score @ 96wk1 mg
absolute change · Z-score
NCT02047734 · Phase 3
show 3 more results
0.003 vs -0.022 Interferon Beta-1a Z-score @ 52wk1 mg
NCT02294058 · Phase 3
0.036 vs -0.052 Interferon Beta-1a Z-score @ 96wk0.5 mg
NCT02047734 · Phase 3
-0.007 vs -0.022 Interferon Beta-1a Z-score @ 52wk0.5 mg
NCT02294058 · Phase 3
New or Enlarging T2 Lesion 1.465 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk1 mg
event count · T2 lesions/scan
NCT02294058 · Phase 3
show 1 more result
2.139 vs 2.836 Interferon Beta-1a T2 lesions/scan @ 52wk0.5 mg
NCT02294058 · Phase 3
MRI T2 Lesion-Free 27.96% (n=447) vs 23.44% (n=448) Interferon Beta-1a @ 52wk1 mg
responder rate · % of participants
NCT02294058 · Phase 3
show 1 more result
26.39% (n=451) vs 23.44% (n=448) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
Brain Volume -0.39% (n=338) vs -0.57% (n=334) Interferon Beta-1a @ 52wk1 mg
percent change · % of baseline
NCT02294058 · Phase 3
show 1 more result
-0.5% (n=347) vs -0.57% (n=334) Interferon Beta-1a @ 52wk0.5 mg
NCT02294058 · Phase 3
Time to First Relapse NA vs NA IFN-B-1a months1.0 mg
time to event · months
Extension (open-label)
NCT02576717 · Phase 3 · registry result, not featured evidence
show 1 more result
NA vs NA IFN-B-1a months0.5 mg
NCT02576717 · Phase 3 · registry result, not featured evidence

+ 21 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fingolimod (Gilenya)'s landscape · ozanimod's landscape